Protest Improper Wage Index Rural Floor on FY 2017 Cost Report

January 24, 2018 Alerts and Newsletters

Download a print-friendly PDF of this Client Alert here.

January 24, 2018

Clients and friends:

As you work to prepare and finalize your hospital's FY 2017 Medicare cost report that is due at the end of February, we want to alert you to an action to take now that may protect your rights in the future. As was widely reported by MHA and in the trade press, the FY 2017 Medicare wage index rural floor for Massachusetts hospitals was understated due to CMS' refusal to correct identified errors in data submitted by Nantucket Cottage Hospital, the state's only rural hospital. The wage index rural floor was set at 1.1822 instead of the correct 1.2659. At least two group appeals were filed at the Provider Reimbursement Review Board (PRRB) contesting the setting of the improperly reduced rural floor. Since the PPRB cannot offer those hospitals relief by voiding a regulation, the issue has proceeded to federal district court in DC, where briefing has begun in the case.

We obviously do not have a crystal ball to predict whether the court litigation will have a favorable result for the hospitals, but, in case the matter does have a positive outcome through a decision or settlement, we recommend that any Massachusetts hospital that was adversely affected by the decreased rural floor preserve any existing rights to relief it may have by filing the wage index amount as a protested item on its FY 2017 cost report. To properly protest an item on the cost report a provider should follow the requirements of 42 CFR 413.24 (j) by: (1) including an estimate of the reimbursement amount for each self-disallowed item, and (2) attaching a separate work sheet that explains why the item was self-disallowed and describes how the estimated reimbursement amount in issue was calculated. Without preserving your rights your institution may be barred from seeking relief on this issue once its NPR for FY 2017 has issued.

We would be happy to discuss this recommendation with you in more detail and answer any questions you may have concerning how to preserve your hospital's rights. We look forward to hearing from you.

___________________________________________________________________
This communication is intended for general information purposes and as a service to clients and friends of Verrill Dana, LLP. This publication, which may be considered advertising under the ethical rules of certain jurisdictions, should not be construed as legal advice or a legal opinion on any specific facts or circumstances, nor does it create attorney-client privilege.

Firm Highlights

Publication/Podcast

FDA Issues Guidance on IRB Review of Non-Emergency Individual Patient Expanded Access Requests for Investigational Drugs and Biological Products to Treat COVID-19

Prompted by a substantial increase in requests for individual patient access to investigational drugs and biologics to treat COVID-19, the U.S. Food & Drug Administration (“FDA”) issued guidance on June 2, 2020 that outlines...

Publication/Podcast

EU-U.S. Privacy Shield Invalidated: Does Your Company Have a Plan B?

On Thursday, July 16, 2020, the Court of Justice of the European Union (“CJEU”) invalidated the EU-U.S. Privacy Shield (“Privacy Shield”) in Data Protection Commissioner v. Facebook Ireland and Maximillian Schrems (Case C-311/18...

Matter

Conflicts of Interest

Reviewed medical center's systems, policies and procedures for identifying, assessing, and managing investigator and institutional conflicts of interest.

News

Michael K. Fee to Lead Verrill’s Nationally-Recognized Health Care and Life Sciences Practice Amidst Recent Changes

(August 31, 2020) – Verrill is pleased to announce Michael K. Fee as the new leader of Verrill’s nationally-recognized Health Care & Life Sciences Group. The Group has a long history of representing a...

Publication/Podcast

FDA Updates its Guidance on Conducting Clinical Trials During COVID-19 Public Health Emergency

On April 16, 2020, the U.S. Food & Drug Administration (“FDA”) again updated its guidance on the “Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency,” adding seven new questions and...

Publication/Podcast

News Flash: HHS Issues Statement Removing Premarket Review Requirements for Laboratory Developed Tests (“LDTs”), Including COVID-19 LDTs

What happened? On August 19, 2020, the U.S. Department of Health and Human Services (“HHS”) issued a single paragraph statement rescinding U.S. Food and Drug Administration (“FDA”) guidance documents concerning premarket review of Laboratory...

Matter

Multi-Site Global Research

Developed and negotiated site and coordinating center agreements in connection with a multi-site, international, National Institutes of Health (NIH)-funded study, and advised on regulatory issues related to the conduct of the study and subsequent...

News

38 Verrill Attorneys, Across Four Offices, Recognized in 2020 Chambers & Partners Guide

(April 27, 2020) – Verrill has been rated as a Leading Firm in a total of ten categories and subcategories as evaluated by London-based Chambers & Partners , one of the world's most respected...

News

Nearly 80 Verrill Attorneys Recognized by Best Lawyers® 2021, Including a Dozen Named Lawyers of the Year

(August 24, 2020) – Nearly 80 Verrill attorneys were recognized as "Best Lawyers" by Best Lawyers® 2021 , including 12 attorneys named “Lawyer of the Year,” a distinguished recognition for only a single lawyer...

Matter

European Union GDPR—Institution

Counseled a preeminent health system and academic medical center on its compliance with the European Union General Data Protection Regulation (GDPR) in relation to its clinical and research activities, including its international research studies...